Share on LinkedInShare on LinkedIn

ARTICLE · 23 MAY 2012

GSK And Genentech Settle Cabilly Patent Lawsuit

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.

United StatesIntellectual Property
Scott Beeser
Scott Beeser

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.  In the lawsuit, started in October 2009, GSK had sought a declaration that the Cabilly II / III patents were invalid, unenforceable and not infringed by the manufacture, use, sale, offer to sell or importation of GSK's ofatumumab (ARZERRA) antibody product. GSK is the development and commercial collaborator of the biotechnology company Genmab A/S.

No further terms of the settlement were disclosed.

Cabilly Background

The Cabilly family of patents generally relate to methods of recombinant antibody production.  The Cabilly II application was filed on June 10, 1988, issued in 2001 and survived an ex parte re-examination by the USPTO in 2009.  Claim 1 of the Cabilly II patent reads as follows:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from